Tepnel Pharmaceutical Services accredited Illumina CSPro for Infinium Genotyping
Tepnel Pharmaceutical Services has been accredited Illumina CSProTM for Infinium genotyping on the Illumina iScan platform, gaining entry to an elite group of Illumina genomics service providers globally.
Tepnel Pharmaceutical Services is an established business of Gen-Probe Incorporated, a world leader in molecular diagnostics.
Illumina CSPro is a collaborative service provider partnership dedicated to ensuring delivery of the highest-quality data available for genetic analysis applications. Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification and on-site audit of the facility and processes.
Dave Scott, General Manager of Tepnel Pharmaceutical Services comments, ‘Our commitment to working in partnership with cutting-edge organisations such as Illumina means that our customers continue to have access to the latest technology. As a high quality, regulatory compliant service provider, we are delighted to gain CSPro certification and to work closely with Illumina to ensure timely and quality delivery of all projects no matter the size’.
‘Illumina CSPro recognises organisations that provide customers with industry-leading data quality and service in genetic analysis,’ says Karen Possemato, Illumina’s Director of Corporate Marketing. ‘Tepnel Pharmaceutical Services is able to provide Infinium Genotyping services using Illumina technology. We are excited to work with them to make it easier for researchers to access the power of Illumina’s genetic analysis technologies.’
Illumina Inc., a San Diego-based company, provides genetic analysis tools to genomic centres worldwide.
